RWA|Tax|Market|Longevity|Archive

Longevity Science Daily

Breakthroughs in anti-aging, regenerative medicine, genomics, and clinical trials

Report Date: 2026-07-18
80+
CRISPR Trials
6
CAR-T Approved
$7.2B
Longevity Market
14
FL Watchlist
Anti-Aging & Senolytics

TAME Trial: Metformin as Anti-Aging Drug

  • First FDA-recognized aging indication trial — 14 US research institutions, 6-year study
  • Targets whether metformin delays onset of age-related diseases

Senolytic Therapy: D+Q

  • Dasatinib + Quercetin selectively eliminates senescent cells
  • Unity Biotechnology UBX1325 in Phase 2 for age-related eye disease
CAR-T: Solid Tumor Breakthroughs

KIR-CAR T Cell Therapy (AACR 2026)

  • Novel KIR-CAR T demonstrates safety and dose-dependent efficacy in solid tumors
  • Universal (off-the-shelf) CAR-T could reduce cost from ~$500K to $50K
CRISPR & Gene Editing

80+ CRISPR Clinical Trials Active

  • Casgevy (Vertex/CRISPR): first approved CRISPR therapy, generating real-world evidence
  • Base editing (Beam Therapeutics): precision without double-strand breaks
  • In vivo LNP delivery (Intellia): durable gene knockdown — potential single-dose cures
Investment Signals
SignalCompanyThesis
ACCUMULATECRSPCasgevy revenue ramp + pipeline
ACCUMULATEVRTXCasgevy partner + CF franchise
SPECULATIVEBEAMBase editing platform
FL Intelligence Brief
Intelligence brief generation failed.
FL AI Intelligence Brief - 3 judgments + 1 action. Not investment advice.
FL Quant Signals - Top 10
TickerPriceSignalRSIMo1M%Mo3M%Mo12M%P/EBeta
JPM341.10HOLD (5/7)63.40+3.5+10.4+19.414.60.98
V358.56HOLD (4/7)66.00+7.6+13.3+3.531.30.75
NVDA202.81HOLD (6/7)58.90-2.2+0.7+17.831.12.21
MSFT393.82HOLD (4/7)63.90-0.0-6.7-22.223.41.13
AAPL333.74HOLD (3/7)88.60+11.5+23.6+58.740.41.10
0700.HK461.60HOLD (4/7)67.80+3.2-9.7-9.716.60.73
9988.HK112.60HOLD (3/7)84.90+5.2-17.0+0.217.70.50
1299.HK75.55HOLD (5/7)67.40+0.5-8.8+14.416.30.64
600519.SS1,253.00BUY (3/7)66.40+3.4-12.3-7.919.00.38
000858.SZ72.76HOLD (6/7)54.80-2.8-27.2-37.222.50.39
48-factor quant screen: 5 US + 3 HK + 2 A-share. 8-strategy majority vote. Not investment advice.
AI Longevity Research Brief
Longevity commentary generation failed.
Generated by FL AI (GLM-4-Plus). Not medical or investment advice.
Cross-Domain Insights
CROSS-DOMAIN INSIGHTS — FOUNT LEGACY DAILY SYNTHESIS 1. RWA Tokenization Meets CRS/FATCA Reporting Exposure As tokenized real-world assets gain traction, fractional ownership structures create blind spots in cross-border tax reporting. Tokenized real estate or private credit held via DeFi rails may bypass traditional CRS/FATCA intermediary reporting. Action: Family office should audit current and planned RWA holdings for reporting gaps, and engage tax counsel to map tokenized positions before OECD closes this loophole. Expect enforcement within 12-18 months. 2. Longevity Assets as Inflation-Resistant Allocation Longevity sector exposure — spanning biotech IP, clinical infrastructure, and senior living real estate — shows low correlation to traditional cyclicals currently under pressure in broader markets. With market volatility elevated, longevity-linked private equity and tokenized healthcare real estate serve as both defensive and growth allocations. Action: Increase longevity weighting by 2-3 percent from traditional equity beta, prioritizing platforms with tokenization-ready IP portfolios. 3. Tax Residency Planning Driven by Longevity Migration Family principals pursuing advanced longevity treatments abroad face unintended tax residency triggers. Extended stays in jurisdictions like Switzerland, Singapore, or Costa Rica for medical purposes can cross the 183-day threshold, creating unexpected tax exposure. Action: Coordinate with tax team to pre-plan medical travel calendars, document treatment necessity, and obtain bilateral residency determinations before commencing cross-border therapies. 4. Market Volatility Accelerates RWA Adoption Timeline Current market dislocation is pushing institutional capital toward tokenized private credit and real estate as yield alternatives. This convergence means RWA liquidity is improving faster than expected, narrowing the illiquidity discount. Action: Reassess RWA position sizing upward — secondary market depth for quality tokenized assets has improved materially, enabling faster rebalancing than traditional private allocations allow.
FL AI scans all 4 daily reports for cross-domain connections. Not investment advice.